Nottingham Community Liver Biomarkers Cohort

Launched by UNIVERSITY OF NOTTINGHAM · Jan 15, 2014

Keywords

ClinConnect Summary

The Nottingham Community Liver Biomarkers Cohort is a clinical trial aimed at identifying and understanding liver disease in people who may not even know they have it. Liver disease is becoming a major health issue, especially in the UK, and many cases are linked to lifestyle factors like drinking too much alcohol, obesity, and type 2 diabetes. This trial is testing new, noninvasive blood tests and imaging techniques to detect liver problems earlier, before they become serious. By inviting patients from local general practices who are at risk for liver disease, the researchers hope to find more cases of early liver scarring and help these individuals make necessary lifestyle changes.

To be eligible for the study, participants must be adults aged 18 or older with certain risk factors, such as consuming more than the recommended amount of alcohol, having type 2 diabetes, being obese, or having persistently elevated liver enzymes. Those who join the study will undergo simple blood tests and, if needed, a noninvasive liver scan. The goal is to see how these tests can predict future liver and heart issues and how they might encourage people to adopt healthier habits. Overall, this trial is an important step towards better understanding and managing liver health in the community.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Adult patients aged 18 years or over (male or female) with primary risk factor for liver disease:
• • Hazardous alcohol use (\>14 units/week for women, \>21 units/week for men)
• • Type 2 Diabetes
• • Obesity
• • Persistently elevated ALT with normal liver serology
• Exclusion Criteria:
• • Active malignancy at study enrolment
• • Inability to provide informed consent for study enrolment
• • Known presence of histologically proven liver disease prior to pilot pathway participation